Q-omics provides the consensus-scored STKLD1 profile across patient tissues and cancer cell-line models. STKLD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, STKLD1 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, STKLD1 RNA expression shows 19,584 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, KICH, and UVM as cancer lineages where STKLD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STKLD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STKLD1 survival associations across molecular data types. STKLD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STKLD1 RNA expression–survival associations across cancer types. High STKLD1 expression shows unfavorable associations in COAD and ACC, but favorable associations in LUAD, PAAD, HNSC and OV. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for STKLD1 RNA expression.
This table summarizes STKLD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for STKLD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STKLD1 shows lower tumor expression in KICH, THCA, KIRC and KIRP and higher tumor expression in LIHC and COAD. The KICH box plot shows higher STKLD1 RNA expression in normal versus tumor tissue (log2 FC = −1.105, t-test p < 0.001).
This table shows molecular features associated with STKLD1 in patient tissues and cancer cell lines. In patient samples, STKLD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STKLD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
